SARS-CoV-2 NSP13 (466-480)
The SARS-CoV-2 non-structural protein 13 (NSP13) sequence DKSAQCFKMFYKGVI (466-480) has been identified as an epitope for anti-viral targeting.
Catalogue number crb1001800 Molecular Weight 1763.9 Sequence (one letter code)
Sequence (three letter code)
Purity >95% Storage -20°C References
Huisman et al., (2022). A high-throughput yeast display approach to profile pathogen proteomes for MHC-II binding. Elife, 11: e78589. doi: 10.7554/eLife.78589.
Kumar et al., (2023). An immunoinformatics approach to study the epitopes of SARS-CoV-2 helicase, Nsp13. Vacunas. doi: 10.1016/j.vacun.2023.02.001.
Rha et al., (2021). SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals. Immune Network, 21(1). doi: 10.4110/in.2021.21.e2.
Manufactured in: United Kingdom
The SARS-CoV-2 non-structural protein 13 (NSP13) has been identified as a target for anti-viral therapeutics due to its highly conserved sequence and is essential for viral replication. NSP13 is part of the helicase superfamily 1B. As an NTPase and RNA helicase, NSP13 binds to RNA-dependent RNA polymerase and acts in concert with the replication-transcription complex to stimulate backtracking and further activate NSP13 helicase activity. These factors make NSP13 a good target for developing new antiviral drugs. In addition, the identification of epitopes within the NSP13 sequence can help design more effective SARS-CoV-2 vaccines.
Models have predicted epitopes exhibiting antigenicity, stability and interactions with MHC class-I and class-II molecules. NSP13 (466-480) is an epitope candidate with various predicted HLA restrictions. This epitope can be used to better vaccine design for more durable CD4+ and CD8+ T cell responses for long-lasting immunity.